While the ACS maintains that it still lacks the scientific evidence to select policies when it come to the long-term effects of vaping, it will now be monitoring emerging data toward that end.
The American Cancer Society has published a new Position Statement which acknowledges that vaping is a viable tobacco harm reduction strategy. It also maps out the scientific evidence for the new position, in addition to policy priorities accordinged to the new data.
When it comes to current clinical recommendations, the Position Statement reads, :
” The ACS has always supported any smoker who is considering quitting, no matter what approach they use … Some smokers, despite firm clinician advice, will not attempt to quit smoking cigarettes and will not use FDA approved cessation mediations. These individuals should be encouraged to switch to the least harmful form of tobacco product possible; switching to the exclusive use of e-cigarettes is preferable to continuing to smoke combustible products.”
Regarding the policy, ACS reveres the FDA but appears to urge the FDA to regulate vaping to the full extent of its authority to execute so, while also suggesting post-market monitoring of vaping products to determine their safety and effectiveness. To wit:
This marks a significant shift from the American Cancer Society’s previous position, and Vape News will be monitoring the regulatory and scientific landscape for any further developments.
” Any related regulatory regime should include post-marketing surveillance to monitor the long-term effects of these products and ensure the FDA’s actions have the intended health outcome of significantly reducing disease and death.”